Edition:
United Kingdom

Arrowhead Pharmaceuticals Inc (ARWR.OQ)

ARWR.OQ on NASDAQ Stock Exchange Global Select Market

13.39USD
16 Nov 2018
Change (% chg)

$0.41 (+3.16%)
Prev Close
$12.98
Open
$12.89
Day's High
$13.54
Day's Low
$12.80
Volume
554,361
Avg. Vol
646,234
52-wk High
$22.38
52-wk Low
$3.01

Chart for

About

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of... (more)

Overall

Beta: 1.91
Market Cap(Mil.): $317.78
Shares Outstanding(Mil.): 74.77
Dividend: --
Yield (%): --

Financials

  ARWR.OQ Industry Sector
P/E (TTM): -- 83.63 33.59
EPS (TTM): -0.67 -- --
ROI: -55.08 -0.64 15.05
ROE: -61.13 0.08 16.62

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion

Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion (2.8 billion pounds), sending its shares surging 20 percent.

04 Oct 2018

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 billion

Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B treatment and buy a minor stake in a deal that could be potentially worth more than $3.7 billion, sending its shares surging 20 percent.

04 Oct 2018

UPDATE 1-J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln

* Shares gain as much as 20 pct premarket (Adds share movement and comment from analyst, CEO)

04 Oct 2018

J&J, Arrowhead in gene-silencing drug deal worth up to $3.7 bln

Oct 4 Arrowhead Pharmaceuticals Inc said on Thursday Johnson & Johnson would develop and market its gene-silencing Hepatitis B drug and pick up a minor stake in the company in a deal that could be potentially worth more than $3.7 billion.

04 Oct 2018

Earnings vs. Estimates